drugset
drugset / Trial / NCT07597772

Preliminary Trial of SNA014 for Pancreatic Cancer

NCT07597772 ↗

Phase 0 Recruiting 12 enrolled SmartNuclide Biopharma Tianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelDiagnostic

Summary

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Timeline

Start
2025-10-01
Primary completion
2026-07-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-NODAGA-SNA006 Protein / enzyme biologic — —

Indications

malignant pancreatic neoplasm